Ground-breaking research by Tseng et al. (2024) presents a compelling case for the use of high-dose omega-3 fatty acids in migraine prevention, which outperformed existing pharmacological options in both efficacy and acceptability.
Study Overview
The researchers conducted a network meta-analysis of 40 randomised controlled trials, involving 6,616 participants (78.9% women, mean age 35 years), to compare the efficacy and acceptability of various dosages of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) with current FDA-approved or guideline-recommended prophylactic treatments for migraine.
Key Findings
High-dose EPA/DHA supplementation:
- demonstrated the most significant decrease in migraine frequency among all studied interventions
- led to the largest decrease in migraine severity
- showed the most favourable acceptability rates among all examined prophylactic treatments
Implications
These findings suggest that high-dose EPA/DHA supplementation could be considered a first-choice treatment for migraine prophylaxis, outperforming existing pharmacological options in both efficacy and acceptability.
This is particularly significant given that current pharmacologic prophylactic strategies for migraine have limited efficacy, with response rates of only 40% to 50%, and often come with safety concerns.
Conclusion
While these results are promising, it is important to note that further research may be needed to confirm the long-term effects and determine optimal dosages of high-dose EPA/DHA for migraine prevention.
Nevertheless, this study opens up new possibilities for those living with migraine, potentially offering a more effective and better-tolerated option for prevention.
Perhaps a powerful complementary ally for combating noxious cervical afferents?
Reference:
